National Pension Service Acquires 19,961 Shares of Moderna, Inc. (NASDAQ:MRNA)

National Pension Service raised its holdings in shares of Moderna, Inc. (NASDAQ:MRNA) by 2.9% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 712,056 shares of the company’s stock after buying an additional 19,961 shares during the period. National Pension Service owned about 0.19% of Moderna worth $70,814,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in the business. The Manufacturers Life Insurance Company grew its holdings in Moderna by 77.3% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 3,876,147 shares of the company’s stock valued at $400,367,000 after buying an additional 1,690,341 shares in the last quarter. Invesco Ltd. boosted its position in shares of Moderna by 19.8% during the third quarter. Invesco Ltd. now owns 3,126,028 shares of the company’s stock worth $322,887,000 after acquiring an additional 517,683 shares during the last quarter. Wellington Management Group LLP grew its stake in Moderna by 9.3% during the third quarter. Wellington Management Group LLP now owns 5,611,119 shares of the company’s stock valued at $579,572,000 after acquiring an additional 476,201 shares in the last quarter. Bamco Inc. NY increased its holdings in Moderna by 4,863.6% in the 3rd quarter. Bamco Inc. NY now owns 426,869 shares of the company’s stock valued at $44,091,000 after acquiring an additional 418,269 shares during the last quarter. Finally, abrdn plc lifted its stake in Moderna by 477.5% in the 4th quarter. abrdn plc now owns 483,574 shares of the company’s stock worth $48,091,000 after purchasing an additional 399,843 shares in the last quarter. 75.33% of the stock is currently owned by institutional investors.

Moderna Stock Up 2.0 %

Shares of MRNA stock traded up $2.47 on Thursday, hitting $124.36. The stock had a trading volume of 1,208,871 shares, compared to its average volume of 4,077,388. Moderna, Inc. has a one year low of $62.55 and a one year high of $142.79. The business has a 50 day moving average price of $106.59 and a 200 day moving average price of $95.24. The company has a market cap of $47.66 billion, a PE ratio of -7.78 and a beta of 1.57. The company has a quick ratio of 3.91, a current ratio of 4.03 and a debt-to-equity ratio of 0.04.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings results on Thursday, May 2nd. The company reported ($3.07) earnings per share for the quarter, topping the consensus estimate of ($3.59) by $0.52. Moderna had a negative net margin of 115.82% and a negative return on equity of 20.10%. The firm had revenue of $167.00 million during the quarter, compared to analysts’ expectations of $93.26 million. During the same quarter in the prior year, the company earned $0.19 EPS. The company’s revenue was down 91.0% compared to the same quarter last year. Research analysts anticipate that Moderna, Inc. will post -7.47 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Moderna news, CFO James M. Mock sold 647 shares of the stock in a transaction on Thursday, February 29th. The stock was sold at an average price of $94.57, for a total transaction of $61,186.79. Following the sale, the chief financial officer now owns 4,300 shares of the company’s stock, valued at approximately $406,651. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Moderna news, Director Noubar Afeyan sold 15,000 shares of the business’s stock in a transaction that occurred on Wednesday, May 1st. The shares were sold at an average price of $110.92, for a total transaction of $1,663,800.00. Following the sale, the director now owns 2,026,931 shares of the company’s stock, valued at approximately $224,827,186.52. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CFO James M. Mock sold 647 shares of Moderna stock in a transaction on Thursday, February 29th. The stock was sold at an average price of $94.57, for a total transaction of $61,186.79. Following the sale, the chief financial officer now owns 4,300 shares of the company’s stock, valued at $406,651. The disclosure for this sale can be found here. Insiders sold 139,954 shares of company stock valued at $14,822,576 over the last 90 days. Corporate insiders own 15.20% of the company’s stock.

Analyst Upgrades and Downgrades

MRNA has been the topic of a number of research analyst reports. Needham & Company LLC reiterated a “hold” rating on shares of Moderna in a research report on Thursday, May 2nd. Oppenheimer upped their price objective on Moderna from $142.00 to $163.00 and gave the stock an “outperform” rating in a report on Friday, May 3rd. Jefferies Financial Group reissued a “buy” rating and issued a $125.00 target price on shares of Moderna in a report on Tuesday, April 9th. William Blair reaffirmed a “market perform” rating on shares of Moderna in a research note on Monday, April 1st. Finally, Canaccord Genuity Group increased their price objective on shares of Moderna from $91.00 to $106.00 and gave the company a “hold” rating in a research report on Friday, May 3rd. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $126.89.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.